The Cancer SIGNAL

When it comes to cancer, there are many types of tests that can provide critical information–tests that can determine one's risk of getting cancer, tests that screen for the presence of cancer, and tests that assess mutations or specific characteristics of a person's cancer to inform treatment paths. Dr. Eric Klein, Distinguished Scientist at GRAIL, joins The Cancer SIGNAL to discuss the different...

Despite significant progress in cancer care, critical health disparities in cancer incidence and outcomes still exist. Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum, joins The Cancer SIGNAL to share his thoughts on improving diversity in clinical trials, the impact of health disparities on cancer outcomes, and why we need to move quickly to expand early cancer detecti...

Cancer is expected to claim the lives of more than 609,000 Americans in 2023 alone, according to the American Cancer Society. Dr. Alpa Patel, Senior Vice President of Population Science at the American Cancer Society, and Dr. Tina Clarke, Epidemiology Vice President and Distinguished Scientist at GRAIL, explore the evolution of how we measure and approach cancer risk and what steps people can take...

March is Colorectal Cancer Awareness Month, and we had the opportunity to feature two guests from the Colorectal Cancer Alliance, a nonprofit whose mission is to provide support to people affected by colorectal cancer, raise awareness of preventive measures and inspire efforts to fund critical research. Michael Sapienza, CEO of the Alliance, and Dr. Charles R. Rogers, an endowed associate professo...

From the early 20th century discovery that cancer is a disease of the genome to having sequenced more than one million humans' genomes today - this is just some of the history Amoolya Singh, Senior Vice President of Data Science and Chief Scientific Officer at GRAIL discusses when she shares the role of genomics and AI in cancer detection, what's needed for population-scale screening tests, and wh...

Valerie kept active, felt healthy, and enjoyed spending time with her friends and family. Although she didn't have symptoms, she took the Galleri test, which found a positive cancer signal. After additional evaluations, it was confirmed she had early-stage gallbladder cancer and was able to take action. Valerie shares her experience taking the test, what the results meant, her treatment journey an...

Step into the lab with Rita Shaknovich, vice president of medical affairs and head of clinical laboratories at GRAIL, as she dives into the science behind the Galleri test and brings to life the process that a Galleri test sample goes through from beginning to end. 

Many U.S. veterans may be at an increased risk of cancer, making access to early detection critical to their health. Dr. Charles Atwood, pulmonologist and lead researcher for the REFLECTION Study at the VA Pittsburgh Healthcare System, joins The Cancer SIGNAL to discuss the work being done to expand early cancer detection for veterans.

GRAIL's founder, Dr. Rick Klausner and president, Joshua Ofman, join host Kim Thiboldeaux to discuss the science behind multi-cancer early detection, the technology being pioneered, and how the tests have the potential to help find cancer earlier in people with elevated risk.

Each month, Kim Thiboldeaux, former CEO and Executive Chair of the Cancer Support Community, will host a discussion around multi-cancer early detection, its origin and promise for anyone at high risk for cancer, the science behind the screening tests, and insight into how this technology has the potential to shift the cancer paradigm. Guests will include healthcare pioneers and providers, advocate...